Page 25 - RPIA_25-2

NOVOS BIOLÓGICOS PARA O TRATAMENTO DA ASMA / ARTIGO DE REVISÃO

31. Gauvreau GM, O Byrne PM, Boulet L -P, Wang Y, Cockcroft D, 34. Kuo C -HS, Stelios Pavlidis, Loza M, Baribaud F, Rowe A, Pandis I, et
Bigler J, et al. Effects of an anti -TSLP antibody on allergen -induced al. Th2 and non -Th2 molecular phenotypes of asthma using sputum
asthmatic responses. N Engl J Med 2014;370(22):2102-10. transcriptomics in UBIOPRED, In Press Eur Respir J 2017;1-14.
32. Gauvreau GM, Harris JM, Boulet L -P, Scheerens H, Fitzgerald JM, 35. Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush
Putnam WS, et al. Targeting membrane -expressed IgE B cell re- A, et al. The burden of severe asthma in childhood and adoles-
ceptor with an antibody to the M1 prime epitope reduces IgE cence: Results from the paediatric U -BIOPRED cohorts. Eur
production. Sci Transl Med 2014;6(243):243ra85. Respir J 2015;46(5):1322-33.
33. Harris JM, Maciuca R, Bradley MS, Cabanski CR, Scheerens H, 36. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield
Lim J, et al. A randomized trial of the efficacy and safety of qui- J, et al. Clinical and inflammatory characteristics of the European
lizumab in adults with inadequately controlled allergic asthma. U -BIOPRED adult severe asthma cohort. Eur Respir J 2015;
Respir Res 2016;17:29. 46(5):1308-21.

113

REVIST A POR TUGUESA DE IMUNO ALERGOLOGIA